-

05:41:10 AM

CARA Stock News

CARA - Cara Therapeutics Inc

08/08/22 4:01 PM

Nasdaq : CARA

earnings

Cara Therapeutics Reports Second Quarter 2022 Financial Results

– Net revenue was $23M for 2Q 2022 comprised of profit-sharing revenue of $8M from KORSUVA ™ (difelikefalin) injection and a $15M milestone payment from the European Commission approval of Kapruvia ® (difelikefalin) – – KOMFORT Phase 2 trial met primary endpoint in notalgia paresthetica, validating

RHEA-AI

positive

08/03/22 7:00 AM

Nasdaq : CARA

conferences

Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive

RHEA-AI

neutral

08/01/22 4:01 PM

Nasdaq : CARA

earnings

Cara Therapeutics to Announce Second Quarter 2022 Financial Results on August 8, 2022

Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio

RHEA-AI

neutral

06/30/22 7:00 AM

Nasdaq : CARA

clinical trial

Cara Therapeutics Announces Positive Topline Results from KOMFORT Phase 2 Trial of Oral Difelikefalin for the Treatment of Pruritus in Patients with Notalgia Paresthetica

– Study achieved primary endpoint of Worst Itch-Numeric Rating Scale score change from baseline at Week 8 (p=0.001) – – Onset of action seen at Week 1 and sustained through Week 8 – – Statistical significance achieved on the WI-NRS ≥ 4-point responder analysis at Week 8 (p=0.007) – – Oral

RHEA-AI

neutral

05/17/22 7:00 AM

Nasdaq : CARA

conferences

Cara Therapeutics to Present at Upcoming Investor Conferences

Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief

RHEA-AI

neutral

05/09/22 4:01 PM

Nasdaq : CARA

earnings

Cara Therapeutics Reports First Quarter 2022 Financial Results

KORSUVA™ (difelikefalin) injection U.S. commercial launch began in April 2022 and is tracking to expectation Kapruvia ® (difelikefalin) approved by European Commission for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult hemodialysis patients, triggering

RHEA-AI

very positive

05/03/22 4:01 PM

Nasdaq : CARA

conferences

Cara Therapeutics to Present at May Investor Conferences

Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief

RHEA-AI

neutral

04/29/22 7:00 AM

Nasdaq : CARA

earnings

Cara Therapeutics to Announce First Quarter 2022 Financial Results on May 9, 2022

Cara Therapeutics, Inc. (Nasdaq: CARA), an early commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and

RHEA-AI

neutral

04/28/22 1:00 AM

Nasdaq, OTC : CARA, GNHAY

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

First approved therapy in Europe for the treatment of chronic kidney disease- associated pruritus in hemodialysis patients First launches in Europe expected in H2 2022. Vifor Fresenius Medical Care Renal Pharma and Cara Therapeutics, Inc. today announced that the European Commission has granted marketing authorization to Kapruvia ® for the treatment...

RHEA-AI

positive

04/28/22 1:00 AM

Nasdaq : CARA

Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients

Vifor Fresenius Medical Care Renal Pharma

RHEA-AI

positive

1 2 3 4 5 6 7 Next

CARA Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.caratherapeutics.com
CeoDerek Chalmers
Security nameCara Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees80
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address4 Stamford Plz
StateConnecticut
CityStamford
Zip06902-3834
CountryUS
Phone12034063700

About Cara Therapeutics Inc

Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs. Cara is developing a novel and proprietary class of product candidates, led by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist that targets the body's peripheral nervous system, as well as certain immune cells. In two Phase 3 trials, KORSUVA injection has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in hemodialysis patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP). Oral KORSUVA™ has successfully completed a Phase 2 trial for the treatment of pruritus in patients with CKD and is currently in Phase 2 trials in atopic dermatitis, primary biliary cholangitis and notalgia paresthetica patients with moderate-to-severe pruritus.